Health
Commented by Nico Popp on October 31st, 2025 | 07:00 CET
Health as a billion-dollar market: PanGenomic Health, Hims & Hers, WW International
More and more people are taking a proactive approach to their health, with prevention and self-care trending. According to recent studies by McKinsey, the global wellness industry is now valued at around USD 2 trillion. Younger generations in particular are integrating health firmly into their lifestyles: nearly 30% of millennials and Gen Z in the US report that they are doing significantly more for their well-being today than they were a year ago. Instead of only taking action when they fall ill, many are focusing on prevention, digital health tools, and online communities for support and exchange. We take a look at the latest trends, revisit familiar names, and highlight an emerging startup that could also deliver healthy returns for your portfolio.
Read
Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST
Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves
The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST
Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus
The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!
Read
Commented by Carsten Mainitz on September 26th, 2025 | 07:35 CEST
Gerresheimer, dynaCERT, Volkswagen – Exciting developments!
News drives prices. However, the pendulum can swing in both directions. For informed investors, the correct interpretation of events is crucial. Often, this then leads to lucrative entry and exit signals. Gerresheimer was the latest to be hit, but which stock could be next? However, there are also stocks that are due for a realignment, offering opportunities for rising prices.
Read
Commented by Nico Popp on September 23rd, 2025 | 07:10 CEST
The AI doctor in your pocket: PanGenomic Health, Bayer, CVS Health
Healthcare costs are a pressing political issue worldwide - in Germany, for example, debates are resurfacing over co-payments and the requirement to see a general practitioner first. This drives more people to self-medicate. The situation is even more extreme in the US: without mandatory insurance and facing extremely high healthcare costs, almost 9% of the population is uninsured, and around 33% is underinsured, leading many citizens to turn to alternative solutions. We examine business models related to increasing personal responsibility in healthcare, with a special focus on a smaller-cap stock.
Read
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Fabian Lorenz on September 12th, 2025 | 07:15 CEST
200% shares Steyr Motors and PanGenomic Health! When will cancer-fighter BioNTech explode?
More than 200% price gains are not enough: Steyr Motors and PanGenomic Health continue to go full throttle. Despite its strong performance in recent weeks, PanGenomic still appears undervalued. With the use of artificial intelligence, the Canadians want to tap into the billion-dollar market for personalized alternative medicine and dietary supplements in North America. Their e-commerce platform has just gone live. Steyr Motors reports several successes in China, opening up a billion-dollar market for the Austrians. In contrast, BioNTech shares are not moving. Yet the Mainz-based company is increasingly becoming a real cancer fighter. Will the stock soon explode?
Read
Commented by André Will-Laudien on August 26th, 2025 | 07:20 CEST
Big moves! Buying frenzy at Novo Nordisk and PanGenomic Health, Valneva left behind
Things are moving again in the biotech sector! While Novo Nordisk appears to have finally found its footing after three profit warnings, PanGenomic Health continues its upward trend. Since launching its new business model in May, the stock has staged a phenomenal rally of over 1,000%. Meanwhile, Valneva faces a major setback as the US Food and Drug Administration (FDA) has halted approval of the chikungunya vaccine Ixchiq due to severe side effects. This comes as a shock to investors, who are now waiting for the Company to provide further explanations. The stock market has reacted with a sharp drop in the share price. How can investors benefit from the current situation?
Read
Commented by Nico Popp on August 18th, 2025 | 07:25 CEST
780% return thanks to expensive medicine: PanGenomic Health, CVS Health, Teladoc Health
Healthcare costs are skyrocketing. According to KFF, a leading US healthcare policy organization, the United States spent around USD 4.5 trillion on healthcare in 2022. That is equivalent to 17% of gross domestic product. Given the millions of Americans who, due to lack of insurance, opt for painkillers instead of visiting a dentist, that is a remarkable figure. KFF also reports that one in four Americans postponed medical treatment last year. In this complex environment, the importance of personal responsibility and self-therapy is growing. Companies are stepping in to address the situation and offer solutions. We present three business models and explain what opportunities they may hold for investors.
Read
Commented by Armin Schulz on August 5th, 2025 | 07:30 CEST
Bayer, PanGenomic Health, Novo Nordisk: 3 stocks that could benefit from the USD 330 billion tech tsunami!
In 2025, the healthcare industry is being hit by a tech tsunami. Telemedicine and digital applications are revolutionizing diagnostics and treatment. Driven by AI, regulatory tailwinds, and rising patient demand, the market is exploding. Forecasts predict growth of up to USD 330 billion by 2029. Investors sense billion-dollar opportunities, especially where biotech meets big data and personalized solutions emerge. To benefit from these developments, key players like Bayer, PanGenomic Health, and Novo Nordisk are already positioning themselves today. We take a closer look at all three.
Read